Modulation of the intramedullary pressure responses by calcium dobesilate in a rabbit knee model of osteoarthritis.

Acta Orthop

Department of Small Animal Clinical Sciences, Faculty of Life Sciences (LIFE), University of Copenhagen, Denmark.

Published: October 2011

Background And Purpose: The presence of bone marrow edema in patients with osteoarthritis is associated with pain and disease progression. Management of bone edema with the synthetic prostacyclin iloprost may be complicated by side effects. Calcium dobesilate, a treatment for chronic venous disease, shares some pharmacological actions with iloprost but appears to be better tolerated. Anecdotal reports have suggested that calcium dobesilate may be useful for medical management of osteoarthritis, possibly by reducing bone marrow edema, and this study was performed to investigate possible benefits of treatment.

Methods: The effects of a 6-week period of oral calcium dobesilate administration on tibial intramedullary pressure dynamics and physical joint characteristics were evaluated in 20 rabbits with unilaterally induced knee osteoarthritis that were randomly allocated to either a treatment group or a placebo control group. Treatment or placebo started 8 weeks after induction of osteoarthritis, and was followed by a 4-week washout period.

Results: Calcium dobesilate did not affect joint thickness or range of motion, nor individual pressure measurements, compared to placebo. Pressure ranges in the operated limb were greater than in the intact limb after 8 weeks, and approached those of the intact limb after 6 weeks of treatment with calcium dobesilate but not with placebo. Inter-limb differences were lower (p = 0.02) in the dobesilate group following the washout period.

Interpretation: Calcium dobesilate had a detectable effect on pressure dynamics in the subchondral bone of osteoarthritic joints in this model. The significance of these effects for pain and function should be established.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242962PMC
http://dx.doi.org/10.3109/17453674.2011.618916DOI Listing

Publication Analysis

Top Keywords

calcium dobesilate
28
intramedullary pressure
8
dobesilate
8
bone marrow
8
marrow edema
8
pressure dynamics
8
intact limb
8
limb weeks
8
calcium
7
pressure
5

Similar Publications

Discovery of a potent, Kv7.3-selective potassium channel opener from a Polynesian traditional botanical anticonvulsant.

Commun Chem

October 2024

Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.

Plants remain an important source of biologically active small molecules with high therapeutic potential. The voltage-gated potassium (Kv) channel formed by Kv7.2/3 (KCNQ2/3) heteromers is a major target for anticonvulsant drug development.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness and safety of two dosages of calcium dobesilate (500 mg vs. 1000 mg) in patients with Chronic Venous Insufficiency (CVI) in CEAP classes C3-C4.
  • A multicenter retrospective analysis monitored patient progress over 12 months, using scores and circumference measurements to gauge improvement.
  • Results showed that the higher dosage (1000 mg) significantly improved symptom relief and reduced limb swelling compared to the lower dosage, indicating a potential benefit of using higher doses for managing advanced CVI.
View Article and Find Full Text PDF

Introduction: SARS-CoV-2 mainly infects respiratory endothelial cells, which is facilitated through its spike protein binding to heparan sulphate. Calcium dobesilate (CaD) is a well-established, widely available vasoactive and angioprotective drug interacting with heparan sulphate, with the potential to interfere with the uptake of SARS-CoV-2 by epithelial cells. The CADOVID trial aims to evaluate the efficacy and safety of CaD in reducing the SARS-CoV-2 viral load in non-hospitalised adult patients diagnosed with COVID-19, confirmed by a positive SARS-CoV-2 PCR, including its efficacy to reduce the impact of persistent COVID-19 symptoms.

View Article and Find Full Text PDF

This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!